相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C. E. Geyer et al.
ANNALS OF ONCOLOGY (2022)
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston et al.
MOLECULAR CANCER THERAPEUTICS (2022)
A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Review Hallmarks of DNA replication stress
Sneha Saxena et al.
MOLECULAR CELL (2022)
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
Hiroyuki Ueno et al.
COMMUNICATIONS BIOLOGY (2022)
Recent advances in therapeutic strategies for triple-negative breast cancer
Yun Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
DNA-PKcs promotes fork reversal and chemoresistance
Diego Dibitetto et al.
MOLECULAR CELL (2022)
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A. Yap et al.
CANCER DISCOVERY (2021)
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
Mark T. J. van Bussel et al.
BRITISH JOURNAL OF CANCER (2021)
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
Tanya E. Keenan et al.
CLINICAL CANCER RESEARCH (2021)
Replication stress: from chromatin to immunity and beyond Yea-Lih Lin and Philippe Pasero
Yea-Lih Lin et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2021)
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers
Daniel J. McGrail et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Laura Cortesi et al.
TARGETED ONCOLOGY (2021)
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
Mark R. Middleton et al.
BRITISH JOURNAL OF CANCER (2021)
Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor.
Ashley P. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
Ke Cong et al.
MOLECULAR CELL (2021)
Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11
Ukhyun Jo et al.
CANCERS (2021)
Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression
Martina Proctor et al.
CANCERS (2021)
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer
Karama Asleh et al.
NPJ BREAST CANCER (2021)
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Manni Wang et al.
MEDCOMM (2021)
Targeting the replication stress response through synthetic lethal strategies in cancer medicine
Natalie Y. L. Ngoi et al.
TRENDS IN CANCER (2021)
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Katherine E. Baillie et al.
TRENDS IN CANCER (2021)
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches et al.
MOLECULAR CANCER THERAPEUTICS (2020)
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models
Antje M. Wengner et al.
MOLECULAR CANCER THERAPEUTICS (2020)
WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer
Andrea Sand et al.
CANCER LETTERS (2020)
Human DNA-PK activates a STING-independent DNA sensing pathway
Katelyn Burleigh et al.
SCIENCE IMMUNOLOGY (2020)
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases
Alexandra S. Zimmer et al.
FUTURE ONCOLOGY (2020)
Role of DNA repair defects in predicting immunotherapy response
Jing Zhang et al.
BIOMARKER RESEARCH (2020)
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Matteo Berti et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
A PhaseIISingle Arm Pilot Study of theCHK1Inhibitor Prexasertib (LY2606368) inBRCAWild-Type, AdvancedTriple-NegativeBreast Cancer
Margaret E. Gatti-Mays et al.
ONCOLOGIST (2020)
Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene
Christopher Butler et al.
TRANSLATIONAL ONCOLOGY (2020)
Topoisomerase 1 prevents replication stress at R-loop-enriched transcription termination sites
Alexy Promonet et al.
NATURE COMMUNICATIONS (2020)
Two replication fork remodeling pathways generate nuclease substrates for distinct fork protection factors
W. Liu et al.
SCIENCE ADVANCES (2020)
Exploiting DNA Replication Stress for Cancer Treatment
Tajinder Ubhi et al.
CANCER RESEARCH (2019)
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Julian Puppe et al.
CLINICAL CANCER RESEARCH (2019)
Phase 1, open-label, dose-escalation study of M3814 ± avelumab radiotherapy (RT) in patients (pts) with advanced solid tumors.
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
Manish R. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Replication-Coupled DNA Repair
David Cortez
MOLECULAR CELL (2019)
Defining and Modulating 'BRCAness'
Andrea K. Byrum et al.
TRENDS IN CELL BIOLOGY (2019)
Replication Stress Response Links RAD52 to Protecting Common Fragile Sites
Xiaohua Wu
CANCERS (2019)
Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer
Deborah Nazareth et al.
CANCERS (2019)
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok et al.
NATURE COMMUNICATIONS (2019)
MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis
Marianne Samir Makboul Issac et al.
NEOPLASIA (2019)
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
Monika Toma et al.
CANCERS (2019)
Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties
Bhanvi Mishra et al.
CANCER BIOLOGY & THERAPY (2019)
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
A. Italiano et al.
ANNALS OF ONCOLOGY (2018)
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
N. J. Birkbak et al.
ANNALS OF ONCOLOGY (2018)
Abstract P6-06-04: Targeting replication stress in triple negative breast cancer treatment regimen: An emerging approach
S Rajamanickam et al.
CANCER RESEARCH (2018)
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
Susan M. Domchek et al.
CANCER RESEARCH (2018)
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
Hana Hanzlikova et al.
MOLECULAR CELL (2018)
PIDD mediates the association of DNA-PKcs and ATR at stalled replication forks to facilitate the ATR signaling pathway
Yu-Fen Lin et al.
NUCLEIC ACIDS RESEARCH (2018)
Targeting the replication stress response in cancer
Josep V. Forment et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
Jone Michelena et al.
NATURE COMMUNICATIONS (2018)
Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype
Daniel J. McGrail et al.
CELL REPORTS (2018)
Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs
Julie M. Diamond et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Juan Jin et al.
NEOPLASIA (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High speed of fork progression induces DNA replication stress and genomic instability
Apolinar Maya-Mendoza et al.
NATURE (2018)
SAMHD1 acts at stalled replication forks to prevent interferon induction
Flavie Coquel et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1
Erkin Erdal et al.
GENES & DEVELOPMENT (2017)
Replication Fork Reversal: Players and Guardians
Annabel Quinet et al.
MOLECULAR CELL (2017)
Restoration of Replication Fork Stability in BRCA1-and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
Angelo Taglialatela et al.
MOLECULAR CELL (2017)
Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent Degradation of Nascent DNA in the Absence of Brca2 and Stable Rad51 Nucleofilaments
Arun Mouli Kolinjivadi et al.
MOLECULAR CELL (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
The impact of replication stress on replication dynamics and DNA damage in vertebrate cells
Herve Techer et al.
NATURE REVIEWS GENETICS (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Replication fork reversal triggers fork degradation in BRCA2-defective cells
Sofija Mijic et al.
NATURE COMMUNICATIONS (2017)
The prognostic significance of Cdc6 and Cdt1 in breast cancer
Ravikiran Mahadevappa et al.
SCIENTIFIC REPORTS (2017)
Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells
S. Kumar et al.
ONCOGENESIS (2017)
DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair
Songmin Ying et al.
CANCER RESEARCH (2016)
Apoptotic activity of 5-fluorouracil in breast cancer cells transformed by low doses of ionizing α-particle radiation
Richard Ponce-Cusi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer
Miroslava Jurikova et al.
ACTA HISTOCHEMICA (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
The antitumor toxin CD437 is a direct inhibitor of DNA polymerase α
Ting Han et al.
NATURE CHEMICAL BIOLOGY (2016)
Replication stress: getting back on track
Matteo Berti et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Targeting BRCA1-and BRCA2-deficient cells with RAD52 small molecule inhibitors
Fei Huang et al.
NUCLEIC ACIDS RESEARCH (2016)
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
Xia Ding et al.
NATURE COMMUNICATIONS (2016)
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T. Williamson et al.
NATURE COMMUNICATIONS (2016)
Replication stress: getting back on track
Matteo Berti et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy
Wenpeng Liu et al.
EBIOMEDICINE (2016)
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
Leisha A. Emens et al.
CANCER RESEARCH (2015)
DNA2 drives processing and restart of reversed replication forks in human cells
Saravanabhavan Thangavel et al.
JOURNAL OF CELL BIOLOGY (2015)
Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells
Ralph Zellweger et al.
JOURNAL OF CELL BIOLOGY (2015)
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Marieke Aarts et al.
MOLECULAR CANCER THERAPEUTICS (2015)
ATR-Mediated Phosphorylation of FANCI Regulates Dormant Origin Firing in Response to Replication Stress
Yu-Hung Chen et al.
MOLECULAR CELL (2015)
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
Remi Buisson et al.
MOLECULAR CELL (2015)
TIPIN depletion leads to apoptosis in breast cancer cells
Celine Baldeyron et al.
MOLECULAR ONCOLOGY (2015)
Exploiting replicative stress to treat cancer
Matthias Dobbelstein et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
DNA replication origin activation in space and time
Michalis Fragkos et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors
Shinya Abe et al.
ONCOTARGET (2015)
ATR inhibition preferentially targets homologous recombination-deficient tumor cells
M. Krajewska et al.
ONCOGENE (2015)
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
J. Balmana et al.
ANNALS OF ONCOLOGY (2014)
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
Edward Sausville et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe
Amanda K. Ashley et al.
DNA REPAIR (2014)
Causes and consequences of replication stress
Michelle K. Zeman et al.
NATURE CELL BIOLOGY (2014)
Phase I: Veliparib with cisplatin (CP) and vinorelbine (VAR) in advanced triple-negative breast cancer (JAW) and/or BRCA mutation-associated breast cancer
Eve T. Rodler et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
Cynthia X. Ma et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
Luis Ignacio Toledo et al.
CELL (2013)
Replication Stress and Chromatin Context Link ATM Activation to a Role in DNA Replication
Monica M. Olcina et al.
MOLECULAR CELL (2013)
Homologous recombination and its regulation
Lumir Krejci et al.
NUCLEIC ACIDS RESEARCH (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski et al.
BREAST CANCER RESEARCH (2012)
Balancing repair and tolerance of DNA damage caused by alkylating agents
Dragony Fu et al.
NATURE REVIEWS CANCER (2012)
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CANCER RESEARCH (2011)
An oncogene-induced DNA damage model for cancer development
Thanos D. Halazonetis et al.
SCIENCE (2008)
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Jirina Bartkova et al.
NATURE (2006)
Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG)
ME Trudeau et al.
ANNALS OF ONCOLOGY (2006)
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
A Jazayeri et al.
NATURE CELL BIOLOGY (2006)
Cellular processing of platinum anticancer drugs
D Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
ATR and ATM regulate the timing of DNA replication origin firing
D Shechter et al.
NATURE CELL BIOLOGY (2004)
Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms -: Intermediacy of H2O2- and p53-dependent pathways
SW Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes
L Zou et al.
SCIENCE (2003)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Apoptosis in normal tissues induced by anti-cancer drugs
T Tamaki et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2003)
Checking on the fork: the DNA-replication stress-response pathway
AJ Osborn et al.
TRENDS IN CELL BIOLOGY (2002)
Cell cycle checkpoint signaling through the ATM and ATR kinases
RT Abraham
GENES & DEVELOPMENT (2001)
Rapid destruction of human Cdc25A in response to DNA damage
N Mailand et al.
SCIENCE (2000)
分享论文
